Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders

Trends Neurosci. 2023 Jan;46(1):60-74. doi: 10.1016/j.tins.2022.10.010. Epub 2022 Nov 8.

Abstract

Schizophrenia remains a major health burden, highlighting the need for new treatment approaches. We consider the potential for targeting the trace amine (TA) system. We first review genetic, preclinical, and clinical evidence for the role of TAs in the aetiopathology of schizophrenia. We then consider how the localisation and function of the trace amine-associated receptor 1 (TAAR1) position it to modulate key brain circuits for the disorder. Studies in rodents using Taar1 knockout (TAAR1-KO) and overexpression models show that TAAR1 agonism inhibits midbrain dopaminergic and serotonergic activity, and enhances prefrontal glutamatergic function. TAAR1 agonists also reduce hyperactivity, attenuate prepulse inhibition (PPI) deficits and social withdrawal, and improve cognitive measures in animal models. Finally, we consider findings from clinical trials of TAAR1 agonists and how this approach may address psychotic and negative symptoms, tolerability issues, and other unmet needs in the treatment of schizophrenia.

Trial registration: ClinicalTrials.gov NCT04512066 NCT03669640 NCT02969382 NCT05359081.

Keywords: antipsychotic; circuits; intracellular signalling; neurotransmitters; pathophysiology; psychosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dopamine
  • Receptors, G-Protein-Coupled / genetics
  • Schizophrenia* / drug therapy

Substances

  • Trace amine-associated receptor 1
  • Receptors, G-Protein-Coupled
  • Dopamine

Associated data

  • ClinicalTrials.gov/NCT04512066
  • ClinicalTrials.gov/NCT03669640
  • ClinicalTrials.gov/NCT02969382
  • ClinicalTrials.gov/NCT05359081